PROSpect’s Negative Findings Are the Most Important Data in Pediatric Critical Care This Decade
The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that...
PharPoint Research Joins Medrio Early Adopter Program for CTMS
PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product launch.
Moleculin Biotech Completes Dosing in Phase 2/3 MIRACLE Trial for AnnAraC
Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected Q1...
Zhimeng Biopharma Completes Enrollment of CB03-154 Phase 2/3 ALS Trial
Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 readout.
When the “Standard of Care” Fails the Trial: What PROSpect’s Negative Findings Reveal About Pediatric Critical Care’s Evidence Crisis
PROSpect's factorial RCT found no benefit from prone positioning or HFOV in moderate-to-severe PARDS, forcing a reckoning with two...
PharPoint shaped Medrio CTMS design through early adopter program
PharPoint Research shaped Medrio CTMS design through early adopter program, influencing clinical trial monitoring workflows before product launch.
TJ101 Achieves 75% Response Rate in Pretreated Urothelial Carcinoma
TJ101 achieves 75% response rate in pretreated urothelial carcinoma patients who previously received enfortumab vedotin and pembrolizumab.
Iovance Adds Biomarker Selection to Lifileucel Lung Cancer Trial
Iovance adds biomarker selection to lifileucel lung cancer trial, shifting to precision patient selection approach for Phase 2 IOV-LUN-202.
Can Psychedelics Restore Consciousness? The Trial Design Problem Nobody Is Ready For
A Molecular Psychiatry review asks whether psilocybin can reach minimally conscious patients, and exposes the outcome measurement gaps trials...
What PPMI’s Pre-Symptomatic Parkinson’s Cohort Teaches Sites About Biomarker-Driven Screening
PPMI's RBD and hyposmia enrollment strategy yields 94% CSF alpha-synuclein positivity, here's what that means for site screening workflows...